CTOs on the Move

Trellis Bioscience

www.trellisbio.com

 
Trellis Bioscience is a leader in identifying rare protective antibodies by screening human blood cells.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Dante Labs

Dante Labs is a global genomic data company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. Our assets include one of the largest private genome databases with research consent, a proprietary software platform designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing. Headquartered in Cambridge, United Kingdom, with a research laboratory in Wolverhampton, Dante Labs supported the UK Government`s urgent requirement to scale-up a high-capacity, highly automated testing solution for Covid-19, including infected patients as well as those with antibodies. Dante Labs was able to deliver by leveraging existing technology that had been developed for whole genome sequencing.

Broncus Technologies, Inc.

Broncus Medical, Inc. is a well-funded, commercial stage company based in San Jose, CA. The Company`s mission is to deliver navigation, diagnostic & therapeutic technologies to treat patients with lung disease. The Company has a comprehensive intellectual property portfolio with over 75 patents including those issued, licensed, and pending. Along with Broncus Medical`s focus on technological advancements, it is committed to providing outstanding value to patients, healthcare professionals, investors and employees.

Ontario Genomics Institute

Ontario Genomics Institute is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Groninger USA

Groninger USA is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Entasis

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of novel clinical and preclinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases.